Cargando…

Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction

Expressions and clinical implications of cancer-testis antigen (CTA) lactate dehydrogenase (LDH)-C4 in hepatocellular carcinoma (HCC) have not been fully elucidated. Herein, expressions of LDHC mRNA in the serum and serum-derived exosomes of early-stage HCC patients were determined using qRT-PCR, an...

Descripción completa

Detalles Bibliográficos
Autores principales: Cui, Zhaolei, Li, Yun, Gao, Yanni, Kong, Lingying, Lin, Yingfeng, Chen, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732326/
https://www.ncbi.nlm.nih.gov/pubmed/33035196
http://dx.doi.org/10.18632/aging.103879
_version_ 1783622069003485184
author Cui, Zhaolei
Li, Yun
Gao, Yanni
Kong, Lingying
Lin, Yingfeng
Chen, Yan
author_facet Cui, Zhaolei
Li, Yun
Gao, Yanni
Kong, Lingying
Lin, Yingfeng
Chen, Yan
author_sort Cui, Zhaolei
collection PubMed
description Expressions and clinical implications of cancer-testis antigen (CTA) lactate dehydrogenase (LDH)-C4 in hepatocellular carcinoma (HCC) have not been fully elucidated. Herein, expressions of LDHC mRNA in the serum and serum-derived exosomes of early-stage HCC patients were determined using qRT-PCR, and the expression of LDH-C4 protein in HCC tissues was detected using high-throughput tissue microarray analysis. It was found that positive rates of LDHC mRNA expressions in the serum and serum exosomes of HCC patients were 68% and 60%, respectively. The AUCs of serum and exosomal LDHC in differentiating HCC patients from healthy controls were 0.8382 and 0.9451, respectively. The serum and exosomal LDHC levels in HCC patients in the treatment group were higher than the levels in the preliminary diagnosis group, but lower than those in the recurrence group. Survival analysis showed that the expression of LDH-C4 was negatively correlated with the prognosis of HCC. The Cox regression analysis showed that an LDH-C4 level was an independent risk factor for the prognosis of HCC patients. Therefore, serum and exosomal LDHC can be used as a biomarker for early diagnosis, efficacy evaluation and recurrence prediction of HCC. Moreover, LDH-C4 can be used as an important reference indicator for monitoring the prognosis of HCC.
format Online
Article
Text
id pubmed-7732326
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Impact Journals
record_format MEDLINE/PubMed
spelling pubmed-77323262020-12-18 Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction Cui, Zhaolei Li, Yun Gao, Yanni Kong, Lingying Lin, Yingfeng Chen, Yan Aging (Albany NY) Research Paper Expressions and clinical implications of cancer-testis antigen (CTA) lactate dehydrogenase (LDH)-C4 in hepatocellular carcinoma (HCC) have not been fully elucidated. Herein, expressions of LDHC mRNA in the serum and serum-derived exosomes of early-stage HCC patients were determined using qRT-PCR, and the expression of LDH-C4 protein in HCC tissues was detected using high-throughput tissue microarray analysis. It was found that positive rates of LDHC mRNA expressions in the serum and serum exosomes of HCC patients were 68% and 60%, respectively. The AUCs of serum and exosomal LDHC in differentiating HCC patients from healthy controls were 0.8382 and 0.9451, respectively. The serum and exosomal LDHC levels in HCC patients in the treatment group were higher than the levels in the preliminary diagnosis group, but lower than those in the recurrence group. Survival analysis showed that the expression of LDH-C4 was negatively correlated with the prognosis of HCC. The Cox regression analysis showed that an LDH-C4 level was an independent risk factor for the prognosis of HCC patients. Therefore, serum and exosomal LDHC can be used as a biomarker for early diagnosis, efficacy evaluation and recurrence prediction of HCC. Moreover, LDH-C4 can be used as an important reference indicator for monitoring the prognosis of HCC. Impact Journals 2020-10-09 /pmc/articles/PMC7732326/ /pubmed/33035196 http://dx.doi.org/10.18632/aging.103879 Text en Copyright: © 2020 Cui et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/3.0/) (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Cui, Zhaolei
Li, Yun
Gao, Yanni
Kong, Lingying
Lin, Yingfeng
Chen, Yan
Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title_full Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title_fullStr Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title_full_unstemmed Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title_short Cancer-testis antigen lactate dehydrogenase C4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
title_sort cancer-testis antigen lactate dehydrogenase c4 in hepatocellular carcinoma: a promising biomarker for early diagnosis, efficacy evaluation and prognosis prediction
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7732326/
https://www.ncbi.nlm.nih.gov/pubmed/33035196
http://dx.doi.org/10.18632/aging.103879
work_keys_str_mv AT cuizhaolei cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction
AT liyun cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction
AT gaoyanni cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction
AT konglingying cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction
AT linyingfeng cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction
AT chenyan cancertestisantigenlactatedehydrogenasec4inhepatocellularcarcinomaapromisingbiomarkerforearlydiagnosisefficacyevaluationandprognosisprediction